| Analysis . | Rifabutin Triple Group . | Bismuth Quadruple Group . | Treatment Difference, % . | P Value for Differencea . | P Value for Noninferiorityb . |
|---|---|---|---|---|---|
| ITT | |||||
| Eradication rate, (%) | 162/182 (89.0) | 163/182 (89.6) | −0.6 | .866 | .001 |
| 95% CI, % | 83.6–92.8 | 84.3–93.2 | −7.1 to 5.9 | ||
| PP | |||||
| Eradication rate, (%) | 157/167 (94.0) | 143/150 (95.3) | −1.3 | .602 | .001 |
| 95% CI, % | 89.3–96.7 | 90.7–97.7 | −6.6 to 4.1 | ||
| MITT | |||||
| Eradication rate, (%) | 162/173 (93.6) | 163/174 (93.7) | −0.04 | .989 | <.001 |
| 95% CI, % | 89.0–96.4 | 89.0–96.4 | −5.5 to 5.4 |
| Analysis . | Rifabutin Triple Group . | Bismuth Quadruple Group . | Treatment Difference, % . | P Value for Differencea . | P Value for Noninferiorityb . |
|---|---|---|---|---|---|
| ITT | |||||
| Eradication rate, (%) | 162/182 (89.0) | 163/182 (89.6) | −0.6 | .866 | .001 |
| 95% CI, % | 83.6–92.8 | 84.3–93.2 | −7.1 to 5.9 | ||
| PP | |||||
| Eradication rate, (%) | 157/167 (94.0) | 143/150 (95.3) | −1.3 | .602 | .001 |
| 95% CI, % | 89.3–96.7 | 90.7–97.7 | −6.6 to 4.1 | ||
| MITT | |||||
| Eradication rate, (%) | 162/173 (93.6) | 163/174 (93.7) | −0.04 | .989 | <.001 |
| 95% CI, % | 89.0–96.4 | 89.0–96.4 | −5.5 to 5.4 |
Abbreviations: CI, confidence interval; ITT, intention-to-treat; MITT, modified intention-to-treat; PP, per-protocol.
P values are 2-sided for comparing the difference of rifabutin triple group and bismuth quadruple group.
P values are 1-sided for comparing the noninferiority of rifabutin triple group and bismuth quadruple group.
| Analysis . | Rifabutin Triple Group . | Bismuth Quadruple Group . | Treatment Difference, % . | P Value for Differencea . | P Value for Noninferiorityb . |
|---|---|---|---|---|---|
| ITT | |||||
| Eradication rate, (%) | 162/182 (89.0) | 163/182 (89.6) | −0.6 | .866 | .001 |
| 95% CI, % | 83.6–92.8 | 84.3–93.2 | −7.1 to 5.9 | ||
| PP | |||||
| Eradication rate, (%) | 157/167 (94.0) | 143/150 (95.3) | −1.3 | .602 | .001 |
| 95% CI, % | 89.3–96.7 | 90.7–97.7 | −6.6 to 4.1 | ||
| MITT | |||||
| Eradication rate, (%) | 162/173 (93.6) | 163/174 (93.7) | −0.04 | .989 | <.001 |
| 95% CI, % | 89.0–96.4 | 89.0–96.4 | −5.5 to 5.4 |
| Analysis . | Rifabutin Triple Group . | Bismuth Quadruple Group . | Treatment Difference, % . | P Value for Differencea . | P Value for Noninferiorityb . |
|---|---|---|---|---|---|
| ITT | |||||
| Eradication rate, (%) | 162/182 (89.0) | 163/182 (89.6) | −0.6 | .866 | .001 |
| 95% CI, % | 83.6–92.8 | 84.3–93.2 | −7.1 to 5.9 | ||
| PP | |||||
| Eradication rate, (%) | 157/167 (94.0) | 143/150 (95.3) | −1.3 | .602 | .001 |
| 95% CI, % | 89.3–96.7 | 90.7–97.7 | −6.6 to 4.1 | ||
| MITT | |||||
| Eradication rate, (%) | 162/173 (93.6) | 163/174 (93.7) | −0.04 | .989 | <.001 |
| 95% CI, % | 89.0–96.4 | 89.0–96.4 | −5.5 to 5.4 |
Abbreviations: CI, confidence interval; ITT, intention-to-treat; MITT, modified intention-to-treat; PP, per-protocol.
P values are 2-sided for comparing the difference of rifabutin triple group and bismuth quadruple group.
P values are 1-sided for comparing the noninferiority of rifabutin triple group and bismuth quadruple group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
